Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead says Teva challenges US patents for Truvada

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industriesis challenging key US patents held by Gilead Scienceson its HIV therapy, Truvada (emtricitabine and tenofovir disoproxil fumarate), several years before they are due to expire. Gilead said on November 14th that it was notified by Teva of an ANDA filing, and that it has 45 days to begin a patent infringement lawsuit; a lawsuit would put an automatic 30-month stay of approval of the ANDA. In the notification letter, Teva alleges that two of the patents associated with emtricitabine (the '245 and '396) – owned by Emory University but licensed to Gilead – are invalid, unenforceable, and/or will not be infringed by Teva's manufacturer of the product described in the ANDA. Gilead said Truvada is protected by 10 patents listed in the FDA's Orange Book, and all 10 patents would need to be invalidated or expired before a generic version of Truvada could be marketed; these patents are set to expire between 2010 and 2021. The '245 and '396 patents each have been awarded paediatric exclusivity, and are set to lose US exclusivity in May 2021 and September 2021, respectively.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts